FDA Clears First Human Study of DYNE-302
FDA cleared Dyne Therapeutics to begin a randomized Phase I study of DYNE-302 in facioscapulohumeral muscular dystrophy. The therapy uses Dyne’s transferrin-receptor-1-targeted delivery platform to carry an siRNA intended to suppress the pathogenic DUX4…
